Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: jackie who wrote (334)	7/11/1999 5:20:00 PM
From: Walkingshadow	Respond to of 3044

Thanks, Jack "....we are in the early running of the race for anti-obesity drugs. The outcome, or even mid-term results, are not clear at all." Yes, and certainly an exciting time! Besides the weight control strategies alluded to previously, there are now a host of genes which have been shown to be related to weight control, beginning with leptin. The question of how weight is controlled---an understanding of which of course providing the basis for therapeutic intervention----is proving to be far more complex than we imagined, as is so often the case. But, while there may be several powerful approaches to weight control which may be developed in the next couple of years based upon our knowledge thus far, it seems clear to me that MLNM will be at the forefront, or at the very least, will profit from the successes of others. And besides, the future of MLNM is not dependent on any success at all in this area; they will profit no matter what products may---or may not---be developed. The only question will be the magnitude of that profit. A breakthrough treatment for obesity developed by MLNM would be a monster, no question. But they've also got their fingers in an increasing number of pies. All of which I like. Regards, Walkingshadow